证券代码：301111 证券简称：粤万年青 公告编号：2025-033 广东万年青制药股份有限公司 关于股东减持股份触及1%的公告 公司股东汕头市银康企业管理咨询合伙企业（有限合伙）、合和投资控股 （广州）合伙企业（有限合伙）保证向本公司提供的信息内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一 致。 广东万年青制药股份有限公司（以下简称"公司"）于 2025 年 7 月 4 日在巨 潮资讯网（www.cninfo.com.cn）披露了《关于持股 5%以上股东股份减持计划的 预披露公告》（公告编号：2025-030）以及《关于控股股东、实际控制人的一致 行动人股份减持计划的预披露公告》（公告编号：2025-031），公司控股股东、 实际控制人之一致行动人汕头市银康企业管理咨询合伙企业（有限合伙）（以下 简称"银康管理"）以及持股 5%以上股东合和投资控股（广州）合伙企业（有限 合伙）（以下简称"合和投资"），分别计划自该公告披露之日起十五个交易日 后的三个月内以集中竞价、大宗交易方式合计减持公司股份不超过 4,800,000 股， 即 ...

陇神戎发涨超10%，奇正藏药此前涨停，粤万年青、新天药业、盘龙药业、佛慈制药等跟涨。 (本文来自第一财经) ...

每经AI快讯，8月4日，中药股探底回升，陇神戎发一度涨超10%，奇正藏药此前涨停，粤万年青、新天 药业、盘龙药业、佛慈制药等跟涨。 （文章来源：每日经济新闻） ...

8月1日，粤万年青大宗交易成交25.8万股，成交额400.16万元，占当日总成交额的1.92%，成交价15.51 元，较市场收盘价18.15元折价14.55%。 ...

（文章来源：每日经济新闻） 每经AI快讯，8月1日，午后中药板块持续逆势拉升，天目药业、华森制药涨停，生物谷一度触及30%涨 停，新光药业、大唐药业涨超10%，亚宝药业、沃华医药、陇神戎发、粤万年青等跟涨。 ...

Group 1 - The A-share traditional Chinese medicine sector is experiencing a significant upward trend, with companies like Tianmu Pharmaceutical and Huasen Pharmaceutical hitting the daily limit increase [1] - Biotech Valley reached a peak of 30cm limit increase, indicating strong market interest and investor confidence [1] - Other companies such as New Light Pharmaceutical and Datang Pharmaceutical saw increases of over 10%, reflecting a broader positive movement in the sector [1] Group 2 - Additional companies including Yabao Pharmaceutical, Wohua Pharmaceutical, Longshen Rongfa, and Guangdong Wannianqing also showed gains, contributing to the overall bullish sentiment in the traditional Chinese medicine market [1]

证券代码：301111 证券简称：粤万年青 公告编号：2025-032 广东万年青制药股份有限公司 关于使用部分闲置募集资金（含超募资金）和自有资金进行 现金管理到期赎回并继续进行现金管理的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 广东万年青制药股份有限公司（以下简称"公司"）于 2024 年 12 月 18 日召 开第三届董事会第四次会议及第三届监事会第四次会议，并于 2025 年 1 月 3 日 召开 2025 年第一次临时股东大会，审议通过了《关于使用部分闲置募集资金 （含超募资金）和自有资金进行现金管理的议案》，同意公司在确保不影响正常 运营和募集资金投资项目建设的情况下，使用不超过人民币 2.5 亿元（含 2.5 亿 元）的闲置募集资金（含超募资金）及不超过人民币 2.5 亿元（含 2.5 亿元）的 自有资金进行现金管理，上述额度自股东大会审议通过之日起 12 个月内有效。 在上述额度和期限范围内，资金可循环滚动使用，并授权公司管理层在额度范 围内行使相关决策权、签署相关合同文件等。具体内容详见公司于 2024 年 12 月 19 日及 ...

7月30日，粤万年青大宗交易成交13万股，成交额204.88万元，占当日总成交额的2.74%，成交价15.76元，较市场收盘价 17.52元折价10.05%。 | 交易日期 | 证券代码 | 证券简称 | 成交价格 | 成交量 | 成交金额 | 买方营业部 | 卖方营业部 | | --- | --- | --- | --- | --- | --- | --- | --- | | | | | (元) | (万股/万份) | (万元) | | | | 2025-07-30 | 301111 | 粤万年青 | 15.76 | 13.00 | | 204.88 万联证券股份有限 | 广发证券股份有限 | | | | | | | | 公司深圳分公司 | 公司汕头迎宾路证 | | | | | | | | | 券营业部 | ...

Market Overview - The Chinese medicine sector rose by 1.0% on July 29, with Foci Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3609.71, up 0.33%, while the Shenzhen Component Index closed at 11289.41, up 0.64% [1] Top Gainers in Chinese Medicine Sector - Foci Pharmaceutical (002644) closed at 10.69, up 9.98% with a trading volume of 841,300 shares and a turnover of 876 million yuan [1] - Zhongsheng Pharmaceutical (002317) also rose by 9.98% to 19.73, with a trading volume of 1,168,400 shares and a turnover of 2.26 billion yuan [1] - Other notable gainers include: - Zhendong Pharmaceutical (300158) up 6.66% to 7.69 [1] - Huasen Pharmaceutical (002907) up 6.50% to 18.51 [1] - Kangjia Pharmaceutical (600557) up 5.61% to 16.58 [1] Top Losers in Chinese Medicine Sector - Qidi Pharmaceutical (000590) fell by 2.65% to 12.13, with a trading volume of 134,500 shares and a turnover of 163 million yuan [2] - Zhenbaodao (603567) decreased by 2.21% to 12.40, with a trading volume of 182,700 shares and a turnover of 227 million yuan [2] - Other notable losers include: - Yunnan Baiyao (000538) down 1.20% to 55.82 [2] - Kangmei Pharmaceutical (600518) down 0.94% to 2.10 [2] Capital Flow Analysis - The Chinese medicine sector saw a net inflow of 798 million yuan from institutional investors, while retail investors experienced a net outflow of 625 million yuan [2][3] - Notable net inflows from institutional investors include: - Zhongsheng Pharmaceutical (002317) with a net inflow of 308 million yuan [3] - Zhendong Pharmaceutical (300158) with a net inflow of 96.32 million yuan [3] - Conversely, significant net outflows from retail investors were observed in: - Zhongsheng Pharmaceutical (002317) with a net outflow of 98.88 million yuan [3] - Zhendong Pharmaceutical (300158) with a net outflow of 65.62 million yuan [3]

Core Viewpoint - The company, Yue Wannianqing, announced a share reduction plan involving its controlling shareholder and significant shareholders, which will not affect the company's control or governance structure [1][2]. Group 1: Share Reduction Plan - The controlling shareholder, Shantou Yinkang Enterprise Management Consulting Partnership, and the shareholder Hehe Investment Holdings plan to reduce their holdings by a total of up to 9,600,000 shares, representing no more than 6.00% of the company's total share capital [1]. - Shantou Yinkang intends to reduce its holdings by up to 4,800,000 shares (3.00% of total share capital), while Hehe Investment also plans to reduce by up to 4,800,000 shares (3.00% of total share capital) [1]. - As of the announcement date, Shantou Yinkang holds 5,861,520 shares (3.66% of total share capital), and Hehe Investment holds 16,000,000 shares (10.00% of total share capital) [1]. Group 2: Company Background - The controlling shareholder of Yue Wannianqing is Guangdong Jino Health Technology Co., Ltd., with actual controllers being Ou Xiantao and Li Yinghua [2]. - The company was listed on the Shenzhen Stock Exchange's Growth Enterprise Market on December 7, 2021, with an initial public offering of 40 million shares at a price of 10.48 yuan per share [2]. - The company raised a total of 419 million yuan from its initial public offering, with a net amount of 370 million yuan after deducting issuance costs [3]. Group 3: Financial Performance - The company reported operating revenues from 2019 to 2024 as follows: 317 million yuan, 341 million yuan, 350 million yuan, 283 million yuan, 292 million yuan, and 279 million yuan [4]. - The net profit attributable to shareholders for the same period was 66.63 million yuan, 62.52 million yuan, 57.18 million yuan, 33.42 million yuan, 33.50 million yuan, and 4.16 million yuan [4]. - The net cash flow from operating activities for the years 2019 to 2024 was reported as 48.70 million yuan, 90.90 million yuan, 71.63 million yuan, 69.88 million yuan, -12.80 million yuan, and 3.21 million yuan [4].